Cargando…

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis

Purpose: There is uncertainty as to which anticoagulant should be used in non-valvular atrial fibrillation (AF) with valvular heart disease. This systematic review and meta-analysis aimed to assess the efficacy and safety of direct-acting oral anticoagulants (DOACs) compared with warfarin in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martha, Januar Wibawa, Pranata, Raymond, Raffaelo, Wilson Matthew, Wibowo, Arief, Akbar, Mohammad Rizki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797143/ https://www.ncbi.nlm.nih.gov/pubmed/35096994 http://dx.doi.org/10.3389/fcvm.2021.764356

Ejemplares similares

Association between direct-acting oral anticoagulants vs. warfarin with the risk of osteoporosis in patients with non-valvular atrial fibrillation
por: Akhtar, Tauseef, et al.
Publicado: (2020)

Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression
por: Wibowo, Arief, et al.
Publicado: (2021)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

The Prognostic Value of Hyponatremia for Predicting Poor Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis
por: Akbar, Mohammad Rizki, et al.
Publicado: (2021)

Hypocalcemia is associated with severe COVID-19: A systematic review and meta-analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Bitar, Yasmin de Souza Lima, et al.
Publicado: (2021)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

The prognostic value of elevated creatine kinase to predict poor outcome in patients with COVID-19 - A systematic review and meta-analysis
por: Akbar, Mohammad Rizki, et al.
Publicado: (2021)

Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis
por: Wibowo, Arief, et al.
Publicado: (2022)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study)
por: Dalmau Llorca, M. Rosa, et al.
Publicado: (2021)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19: A systematic review and meta-analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
por: Briasoulis, Alexandros, et al.
Publicado: (2018)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021)

Left and right ventricular longitudinal strains are associated with poor outcome in COVID-19: a systematic review and meta-analysis
por: Wibowo, Arief, et al.
Publicado: (2021)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
por: Generalova, Daria, et al.
Publicado: (2020)

Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis
por: de Souza Lima Bitar, Yasmin, et al.
Publicado: (2019)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Healthcare Resource Utilization for Oral Anticoagulant Reversal Therapies in Non-Valvular Atrial Fibrillation/Venous Thromboembolism Patients
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Impact of age on thromboembolic events in patients with non‐valvular atrial fibrillation
por: Kim, Yun Gi, et al.
Publicado: (2019)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
por: Lin, Yu-Sheng, et al.
Publicado: (2021)

A Study of Cardiogenic Stroke Risk in Non-valvular Atrial Fibrillation Patients
por: Song, Ziliang, et al.
Publicado: (2020)

Expression Profiles of Circular RNA in Human Atrial Fibrillation With Valvular Heart Diseases
por: Zhu, Xiyu, et al.
Publicado: (2020)

Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation
por: Balcı, Kevser Gülcihan, et al.
Publicado: (2016)

Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
por: Welander, Frida, et al.
Publicado: (2023)

SAIL study of stroke, systemic embolism and bleeding outcomes with warfarin anticoagulation in non-valvular atrial fibrillation (S(4)-BOW-AF)
por: Harris, Daniel E, et al.
Publicado: (2023)

Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?
por: Lee, So-Ryoung
Publicado: (2019)

Risk Stratification and Anticoagulation in Low-risk Non-valvular Atrial Fibrillation
por: Arya, Arash
Publicado: (2013)

Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
por: Wu, Jia, et al.
Publicado: (2020)

Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation
por: Shang, Luxiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1m9h11p0supl1vi7ncp7ffantu